Yes, I’m happy to respond. Of course, this particular drug has an average six months of extra life, and it’s about the value and the cost of that. Again, these are really difficult assessments to make, which is why, frankly, politicians are often the worst people to try and make that assessment. However, on the broader point about the understanding of what is in the pipeline, I’ve actually had, in recent months, a very sensible conversation with the Association of the British Pharmaceutical Industry and their Wales rep board member, who happens to work for Roche, which is a matter of coincidence, about the manner in which we have conversations as drugs are being developed, and at what point in time the pharmaceutical industry can have that conversation with governments and with appraisal bodies. Because the sooner you know something’s potentially available, the earlier you are able to plan.

Actually, that sort of grown-up approach is really important for us, because the NHS has to be able to try and budget for new treatments coming on board. It has to be able to try and plan the infrastructure around those as well, which is often more important than the cost of paying the medication costs. It’s then also about the industry understanding that it has an interest in being open at a slightly earlier stage with us about what is coming down the line. Otherwise we’ll end up having these sorts of fights on a basis that isn’t good for them as an industry partner, isn’t good for the health service, but ultimately isn’t good for the individual citizens who are then caught up in a campaign between different parts of the public sector and the industry, who are trying to offer a treatment that they are saying will provide a real benefit for them.

So, I’m optimistic that we are continuing to have that grown-up and necessary conversation about the way in which we work together and to understand our competing interests. I don’t try to say to the pharmaceutical industry that they should not be entitled to make a profit in the way they run their business and what they put into developing new treatments, but it has to come at a price that is affordable for the taxpayer and with real value in terms of improving outcomes for the individual citizen as well.